REV1 and neoplasm: Currently, there is some evidence that inhibition of TLS polymerase including REV1 not only sensitizes tumor cells to chemotherapeutic drugs, but also reduces the acquisition of drug-induced mutations associated with tumor resistance (Xie et al., 2010).